G. Skailes

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Ignace Vergote, Corneel Coens, Matthew Nankivell et al. · The Lancet Oncology · 2018 · 290 citations · Full text

Surgical Oncology, Gynecological Surgery, Individual Patient Data +10

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Siow Ming Lee, Iftekhar Khan, Sunil Upadhyay et al. · The Lancet Oncology · 2012 · 176 citations · Full text

Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial

M. Nicolson, Dean A. Fennell, David Ferry et al. · Journal of Thoracic Oncology · 2013 · 60 citations · Full text

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

Susana Banerjee, G. Rustin, James Paul et al. · Annals of Oncology · 2012 · 46 citations · Full text

Oncology, Anzgog Study, Medicine +9

TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy.

S. Lee, R.M. Rudd, Imran Khan et al. · Journal of Clinical Oncology · 2010 · 27 citations

Cancer Management, Pharmacotherapy, Poor Performance Status +17